Company profile: Novellus Therapeutics
1.1 - Company Overview
Company description
- Provider of engineered cellular medicines using non-immunogenic mRNA molecules to safely and efficiently reprogram and gene-edit cells, engineering precision medicines for patient segments via a technology toolbox spanning in vivo and ex vivo applications, including allogeneic and autologous approaches.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Novellus Therapeutics
DST Diagnostische Systeme
HQ: Germany
Website
- Description: Provider of in-vitro diagnostic tests and products for allergy and food intolerance, developing, manufacturing and marketing laboratory and point-of-care systems. Offerings include sIgE rapid tests, LIA ALLERGY LINE kits, NutriSMART rapid tests, NutriLAB ELISA kits, over 600 allergen extracts for diagnostic use and IVD manufacturers, and laboratory services with reports and dietary recommendations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DST Diagnostische Systeme company profile →
Biotheryx
HQ: United States
Website
- Description: Provider of clinical-stage protein degrader therapies, including the PRODEGY platform for targeted protein degradation; PHM molecular glues that use the body’s protein disposal system to selectively degrade disease-causing proteins; BTX-A51, an oral multi-kinase inhibitor for relapsed/refractory AML and high-risk MDS; and a pipeline of first-in-class molecular glue and bifunctional degraders for oncology and inflammatory disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biotheryx company profile →
Nuvig Therapeutics
HQ: United States
Website
- Description: Provider of therapies that induce natural mechanisms to restore immune homeostasis, including NVG-2089, a recombinant, non-immunosuppressive immunomodulator targeting type II Fc receptors to reduce autoimmune dysregulation, in clinical development for inflammatory myopathies and dermatologic autoimmune diseases; recombinant proteins activating immune regulatory receptors; and engineered therapeutic antibodies for autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nuvig Therapeutics company profile →
Viridian Therapeutics
HQ: United States
Website
- Description: Provider of treatments for patients suffering from diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viridian Therapeutics company profile →
Kither Biotech
HQ: Italy
Website
- Description: Provider of pharmaceutical drug development targeting chronic inflammatory diseases, with inhaled therapies such as KIT2014, a cAMP-modulating peptide add-on for cystic fibrosis that enhances CFTR function, reduces mucus, and limits airway inflammation, and KITCL27, an inhaled PI3K-inhibitor prodrug for idiopathic pulmonary fibrosis activated in target cells to minimize systemic side effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kither Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Novellus Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Novellus Therapeutics
2.2 - Growth funds investing in similar companies to Novellus Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Novellus Therapeutics
4.2 - Public trading comparable groups for Novellus Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →